Document is current
Any future updates will be listed below
-
Authors
- License Information
-
More Information
Article History
Received: 22 March 2026
Accepted: 14 May 2026
First Online: 2 July 2026
Declarations
:
: Pascal Joly is consultant for Amgen, Argenx, AstraZeneca, Thermo Fisher, Sanofi, Akari, Janssen, Novartis, Servier, Chugai, Kezar Life Science, Regeneron, UCB, Principabio, Zenyaku Kogyo, Dualyx, JJP Biologics. Vivien Hébert is consultant for AstraZeneca, Pfizer, Almirall, UCB, Lilly, Abbvie, BMS. Camille Kieffer and Billal Tedbirt declare no conflicts of interest.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
